Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by mercedesmanon Aug 17, 2023 3:29pm
260 Views
Post# 35593537

Vantive....

Vantive....

Baxter Announces Vantive as the Name of Proposed Kidney Care Spinoffd 


https://www.baxter.com/baxter-newsroom/baxter-announces-vantive-name-proposed-kidney-care-spinoff

Vantive is expected to launch as an independent, publicly traded company by July 2024 or earlier,...

"We are eager to continue collaborating with the kidney and critical care communities as we work to transform care globally.”

"As a standalone entity with its own investment priorities and enhanced management focus, Vantive should be better positioned to pursue growth opportunities and invest in innovation."




Let's hope that Spectral Mgt. & by association, shareholders will be able to take full "ad-vantive" of the situation that is brewing.

MM
<< Previous
Bullboard Posts
Next >>